CION Ameerpet
Diagnosis Guide · Reviewed by CION Oncologists · NABH Accredited
Clear Cell Cervical Cancer — A Rare Type, Explained
If your pathology report says clear cell carcinoma of the cervix, you have been given a diagnosis that most women have never heard of — and that many general searches answer badly, because the results mix it up with clear cell cancers of the kidney and the ovary. This page deals only with the cervix. Clear cell cervical cancer is an uncommon subtype of adenocarcinoma, it is usually not driven by HPV, and it is staged and treated within the same FIGO framework used for every other cervical cancer. What follows is what the words on your report mean, what tests come next, and how the plan is built at CION's 7 NABH-accredited Hyderabad locations.
- A subtype, not a separate disease — clear cell carcinoma is one variety of cervical adenocarcinoma
- Usually HPV-independent — which is why a negative HPV test never rules this diagnosis out
- Stage still drives the plan — the same FIGO stages, the same surgery and chemoradiation decisions
- Rare tumours belong in a tumour board — every CION cancer plan is agreed by the full team, not one doctor
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What “Clear Cell” Actually Means on Your Report
Cervical cancers are named after the cell they grow from. Roughly seven in ten arise from the flat squamous cells covering the outer cervix; most of the rest are cervical adenocarcinomas, which start in the glandular cells lining the cervical canal. Clear cell carcinoma is one variety of adenocarcinoma, and it takes its name from nothing more dramatic than what the pathologist sees: the cells are packed with glycogen, so once the tissue has been processed for the slide, the cytoplasm washes out and looks empty, or clear.
Three things follow from that, and they are the three things worth understanding before your next appointment.
- It is genuinely rare. Adenocarcinomas are the minority of cervical cancers, and clear cell carcinoma is a small subset within them. Most oncologists in general practice see very few. That is an argument for a centre with a working tumour board, not a reason for alarm.
- The name is shared with other cancers. Clear cell carcinoma also occurs in the kidney, the ovary and the lining of the womb. They behave differently and are treated differently. Search results that mix them together are not describing your diagnosis.
- It is usually HPV-independent. Almost all cervical cancer is caused by persistent high-risk HPV infection. Clear cell carcinoma is one of the exceptions, which changes how it is found — but not how it is staged.
Being HPV-independent is the single most practical fact on this page. It explains why some women with this diagnosis had a negative HPV test not long before, and why they were told their screening was clear. It also means the reassurance a normal HPV result usually offers does not apply here — symptoms still need investigating on their own merit.
Did You Know? The way pathologists classify cervical adenocarcinoma changed in 2020. The fifth edition of the WHO classification of female genital tumours split these cancers into two families — HPV-associated and HPV-independent — because the two groups differ in how they arise, how they are detected and how they behave. Clear cell carcinoma sits in the HPV-independent family. If your report was issued after that change, expect to see that wording on it. Source: WHO Classification of Tumours, Female Genital Tumours, 5th edition (2020).
Who Gets Clear Cell Cervical Cancer — and the DES Question
This subtype has an unusual age pattern, and a piece of medical history attached to it that generates a great deal of anxious searching. Here is what is relevant to a woman diagnosed in India today.
Age pattern
Two Peaks, Not One
Unlike squamous cervical cancer, which clusters in middle age, clear cell carcinoma has long been described with a two-peak age distribution — a small group of very young women, and a larger group at or after the menopause. A diagnosis in your twenties is unusual but not unheard of.
Historical cause
The DES Story
Between the 1940s and the early 1970s, a synthetic oestrogen known as DES was prescribed to some pregnant women in the United States and parts of Europe. Daughters exposed to it before birth were later found to have a raised risk of clear cell cancer of the vagina and cervix, usually appearing in adolescence or early adulthood.
Indian context
Most Cases Have No DES Link
DES was never in routine use in India, and it was withdrawn from obstetric use worldwide decades ago. Almost every Indian woman diagnosed with clear cell cervical cancer today has no such exposure — the tumour arose without it. If you are under 50, your mother's pregnancy is very unlikely to be the explanation.
Not inherited
Not a Family Cancer
Clear cell cervical cancer is not a hereditary cancer syndrome. Your daughters and sisters do not need genetic testing because of this diagnosis, and they should continue with ordinary cervical screening and HPV vaccination on the usual schedule.
Screening
Why Screening Can Miss It
Glandular cancers begin higher inside the cervical canal, where a smear brush reaches less reliably than it does the outer surface, and an HPV-independent tumour will not be flagged by an HPV test. Screening remains essential — it simply is not a guarantee for this particular subtype.
First symptoms
How It Usually Announces Itself
Most often as abnormal vaginal bleeding — between periods, after sex, or after the menopause — or as a persistent watery discharge. These are the same symptoms as any cervical cancer; nothing about them points to the subtype.
None of this changes your treatment. It matters because women are often told, incorrectly, that a cervical cancer diagnosis always means an HPV infection they should feel responsible for. With this subtype, usually it does not.
How the Diagnosis Is Confirmed
The subtype is a tissue diagnosis. No scan, blood test or smear can establish it — only a pathologist looking at cells from the tumour, which is why the sequence below always ends in a laboratory.
1. Colposcopy and biopsy
The cervix is examined under magnification and a small piece of the abnormal area is taken. Because glandular tumours can sit inside the canal rather than on the visible surface, a sample from within the canal is often taken at the same time. Some women need a larger loop or cone specimen before the diagnosis can be made with confidence.
2. Microscopy and immunohistochemistry
The clear cytoplasm and the characteristic architecture are recognised on the standard slide. A panel of immunohistochemical stains is then used to confirm the subtype and to exclude look-alikes — principally clear cell cancers arising in the uterine lining or the ovary, and other glandular cervical tumours. Markers of HPV association are usually absent, which is part of the definition rather than an error.
3. Ruling out the mimics
This is the step most worth a second opinion. A clear cell tumour high in the canal can be difficult to separate from one that began in the endometrium and grew downwards; the two are staged and treated differently. Where there is any doubt, a review of the original slides at a cancer centre is a reasonable and routine request, not a criticism of the first laboratory.
If your report reads differently from what you expected: some rare cervical tumours are reported as mixed or as another rare subtype altogether — see small cell and neuroendocrine cervical cancer, which is a distinct entity with its own treatment pathway, and the broader cervical cancer overview for how the types fit together. Bring the report itself to your consultation — the exact wording changes what is recommended.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Rare Subtype Deserves a Full Team
Every cancer diagnosis at CION goes to a multidisciplinary tumour board before a plan is proposed — surgery, radiation and medical oncology in the same room. Same-week appointments across 7 NABH-accredited Hyderabad locations.
Staging Comes Next — and It Follows the Ordinary Rules
Once the subtype is confirmed, the question changes from what is it to how far has it gone. Clear cell carcinoma is staged with the same FIGO system used for every cervical cancer, and the tests are the same ones.
Examination and pelvic MRI
An examination establishes the size of the tumour and whether it has spread into the tissue beside the cervix or down into the vagina. A pelvic MRI then measures all of that far more precisely than fingers can, and it is the imaging test on which local staging chiefly rests.
PET-CT where the disease is more than early
For larger tumours, or where nodes look suspicious on the MRI, a PET-CT looks at lymph nodes and the rest of the body in a single study. Node status is now part of the stage itself under the 2018 FIGO revision, so this is not an optional extra where it is indicated.
The stage, agreed by the team
Examination findings, pathology and imaging are brought together to assign a FIGO stage, which is what determines whether the plan begins with surgery or with radiation. For an uncommon histology, that discussion happens in the tumour board rather than in a single clinic room — both NCCN and ESMO guidance place multidisciplinary review at the centre of cervical cancer care.
How Clear Cell Cervical Cancer Is Treated
There is no separate treatment pathway for this subtype in the major guidelines. Because it is rare, no large randomised trial has ever compared treatments in clear cell cervical cancer alone, so NCCN and ESMO guidance treats it within the general cervical cancer algorithm, decided by stage.
- Early, confined to the cervix. Surgery is usually the first option — removal of the uterus and cervix with the surrounding supporting tissue, and assessment of the pelvic lymph nodes. Radiation is added afterwards only if the operative specimen shows features that call for it.
- Locally advanced. The standard is radiation given together with platinum-based chemotherapy, completed with brachytherapy — internal radiation delivered directly to the cervix. Brachytherapy is not an optional finishing touch; guideline bodies are unambiguous that omitting it worsens outcomes.
- Spread beyond the pelvis. Treatment becomes systemic, with radiation used where a specific site needs controlling. Which systemic option applies depends on tests run on your tumour tissue.
- Fertility. Fertility-sparing surgery is possible in carefully selected early cervical cancers. Whether it is appropriate for an uncommon histology is a case-by-case decision that should be raised before treatment starts, not after.
We deliberately do not name specific medicines on this page. Which agents are used, in what sequence, and what they cost is set out on our cervical cancer treatment in Hyderabad page, where it can be kept current and read alongside the practical details of scheduling, insurance and scheme cover.
Where Clear Cell Sits Among the Cervical Cancer Types
Your report names one of these. The differences matter for how the cancer was found and how closely it is followed — less so for the treatment itself, which is driven by stage.
| Type on your report | How common | Relationship to HPV | What it changes |
|---|---|---|---|
| Squamous cell carcinoma | The large majority of cervical cancers | Almost always HPV-associated | The reference case — screening detects it well |
| Adenocarcinoma | The main minority type | Usually HPV-associated | Arises in the canal, so cytology finds it less reliably |
| Clear cell carcinoma | Rare — a small subset of adenocarcinomas | Usually HPV-independent | A negative HPV test is not reassurance; slide review is worthwhile |
| Adenosquamous / mixed | Uncommon | Usually HPV-associated | Both cell patterns present; managed on stage |
| Small cell / neuroendocrine | Rare | Often HPV-associated | The one subtype with a genuinely different treatment pathway |
The subtype is only one line of your report. Grade, depth of invasion, margins and lymphovascular invasion sit alongside it, and together they shape what is recommended after surgery.
Did You Know? For rare tumours, the guidelines themselves recommend the team over the individual. Both the ESMO Clinical Practice Guidelines for cervical cancer and the NCCN Guidelines state that treatment planning should be multidisciplinary, and both single out uncommon histologies as the situation where that matters most — because no single specialty sees enough of them to rely on personal experience alone. Asking “has my case been to a tumour board?” is a fair and useful question. Sources: ESMO Clinical Practice Guidelines, Cervical Cancer; NCCN Guidelines for Cervical Cancer.
Why Women With Rare Cervical Tumours Come to CION
An unusual diagnosis needs a team that will read the report carefully and say what it does and does not change.
Tumour board for every diagnosis
Pathology review in-house
17 oncologists across specialties
Woman doctor available on request
45-minute detailed consultation
MRI, PET-CT and brachytherapy coordinated
7 NABH-accredited Hyderabad locations
EMI facility & insurance accepted
4.8 / 5 Google rating
Take The Next Step
Bring the Report. We Will Explain Every Line of It.
A rare subtype is unsettling mostly because so little of what you read online is about it. One consultation with the actual report in hand usually settles more than a week of searching.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Clear Cell Cervical Cancer — Frequently Asked Questions
My HPV test was negative. How can I have cervical cancer?
Because clear cell carcinoma is one of the cervical cancers that does not depend on HPV. In the WHO classification, cervical adenocarcinomas are divided into HPV-associated and HPV-independent groups, and clear cell carcinoma sits in the second. A negative HPV test tells you that you do not have a high-risk HPV infection; it does not tell you that you do not have this tumour. This is also why symptoms — particularly bleeding after sex, bleeding between periods or bleeding after the menopause — are investigated on their own merit rather than being dismissed because a recent screening test was clear.
How rare is clear cell carcinoma of the cervix?
Rare enough that most gynaecologists will see only a handful in a career. Adenocarcinomas make up the minority of cervical cancers, and clear cell carcinoma is a small subset within that minority. Practically, rarity has two consequences. First, it is worth having the slides reviewed at a cancer centre, because the main difficulty in diagnosis is separating a clear cell tumour of the cervix from one that began in the lining of the womb. Second, the plan should come from a multidisciplinary tumour board rather than a single opinion, which is how every cancer diagnosis is handled at CION.
Was my cancer caused by DES exposure before I was born?
Almost certainly not, if you were born in India. DES was a synthetic oestrogen prescribed to some pregnant women in the United States and parts of Europe between the 1940s and the early 1970s, and daughters exposed before birth were later found to have a raised risk of clear cell cancer of the vagina and cervix. It was never in routine obstetric use in India and was withdrawn worldwide decades ago. The great majority of clear cell cervical cancers diagnosed today, in India and elsewhere, occur in women with no DES exposure at all. There is usually no identifiable cause, and nothing you did brought it on.
Does clear cell cervical cancer need different treatment from other types?
Generally no. The major guidelines, including NCCN and ESMO, place clear cell carcinoma inside the standard cervical cancer algorithm, where the stage decides the plan: surgery for disease confined to the cervix, radiation given together with platinum-based chemotherapy and completed with brachytherapy for locally advanced disease, and systemic treatment when disease has spread beyond the pelvis. The subtype influences how carefully the pathology is reviewed and how closely you are followed afterwards, rather than which modality you receive. Specific medicines and costs are covered on our cervical cancer treatment in Hyderabad page.
Can a Pap smear miss this subtype?
It can, and understanding why is useful. A smear samples cells from the surface of the cervix and the opening of the canal. Glandular cancers, including clear cell carcinoma, often begin higher inside the canal where the brush reaches less reliably, and abnormal glandular cells are harder to interpret than abnormal squamous ones. Add the fact that this subtype is usually HPV-independent, so co-testing does not flag it either, and you have a tumour that screening is not designed to catch. That is an argument for taking symptoms seriously, not for skipping screening, which remains highly effective against the common types.
Medical disclaimer: This page is general health information, reviewed by a CION oncologist. It is not a diagnosis and cannot replace review of your own pathology report and scans by a treating team. Rare subtypes vary in how they behave, and nothing here should be used to predict the course of an individual case.